STOCK TITAN

Ameriprise Financial Announces Additional $2.5 Billion Share Repurchase Authorization

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
buyback
Rhea-AI Summary

Ameriprise Financial has announced a $2.5 billion share repurchase program authorized by its Board of Directors, intended to enhance shareholder value and confidence in the company’s future. The buyback will be funded through existing working capital and future earnings, with flexibility regarding the timing and methods of purchases. As of June 30, 2020, about $500 million remains from a previous authorization, valid until March 31, 2021. The program will continue until September 30, 2022, but carries risks regarding execution and market conditions.

Positive
  • Authorization of $2.5 billion share repurchase program to enhance shareholder value.
  • Funding through existing working capital and future earnings may positively impact EPS.
  • Existing authorization of $500 million available indicates confidence in financial strength.
Negative
  • Repurchase program carries risks and uncertainties regarding market execution.
  • No minimum share purchase commitment may lead to inconsistent buybacks.

MINNEAPOLIS--()--The Board of Directors of Ameriprise Financial, Inc. (NYSE: AMP) has authorized an additional $2.5 billion for the repurchase of shares of its common stock through September 30, 2022. As of June 30, 2020, the company had approximately $500 million available from its February 2019 authorization, which is available through March 31, 2021.

The company intends to fund share repurchases through existing working capital, future earnings and other customary financing methods. The share repurchase program does not require the purchase of any minimum number of shares, and depending on market conditions and other factors, these purchases may be commenced or suspended at any time without prior notice. Acquisitions under the share repurchase program may be made in the open market, through privately negotiated transactions or block trades or other means.

This news release contains certain forward-looking statements regarding the timing and manner of, and the sources of funding for, the company’s purchase of shares pursuant to the share repurchase program. Such statements reflect management’s plans, estimates and beliefs, and are subject to risks and uncertainties, which could cause actual results to differ materially from such statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained in this release, which speak only as of the date hereof. We undertake no obligation to update publicly or revise such forward-looking statements.

At Ameriprise Financial, we have been helping people feel confident about their financial future for more than 125 years. With a nationwide network of 10,000 financial advisors and extensive asset management, advisory and insurance capabilities, we have the strength and expertise to serve the full range of individual and institutional investors’ financial needs. For more information, visit ameriprise.com.

© 2020 Ameriprise Financial, Inc. All rights reserved.

Contacts

Paul Johnson
Ameriprise Financial
612.671.0625
paul.w.johnson@ampf.com

FAQ

What is the purpose of Ameriprise Financial's $2.5 billion stock buyback?

The purpose is to enhance shareholder value and demonstrate confidence in the company's future.

When does Ameriprise Financial plan to complete its share repurchase program?

The share repurchase program is scheduled to continue until September 30, 2022.

How will Ameriprise Financial fund its share buyback program?

Ameriprise Financial plans to fund the buyback through existing working capital, future earnings, and other financing methods.

How much was remaining from the previous buyback authorization as of June 30, 2020?

As of June 30, 2020, approximately $500 million remained from the previous authorization.

Ameriprise Financial, Inc.

NYSE:AMP

AMP Rankings

AMP Latest News

AMP Stock Data

54.11B
96.83M
0.17%
87.25%
1.16%
Asset Management
Investment Advice
Link
United States of America
MINNEAPOLIS